Volumen: 14 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2010
Authors: Agriello E., Barcala V., Bergna M., Cismondi V., Ensinck A., Escalada A., Fiorenza G., Giordano H., Halperin N., Monreal M., Novoa A., Novoa V., Pardo L., Sánchez, A.
Abstract: Flow cytometry (FC) identifies and quantifies cell surface and cytoplasmic antigens that are highly regulated during maturation from hematopoietic stem cells to fully functional mature cells in peripheral blood. Various studies have confirmed the useful role of FC in the evaluation of myelodysplastic syndromes (MDS), and as from 2006, FC has become a useful adjunct (co-criteria) in patients with questionable clinical and morphological criteria. The regulation of antigen expression characteristic of normal hematopoietic stem cell maturation is lost in neoplastic processes, giving rise to abnormal phenotypic patterns. FC assists in the study of MDS patients by identifying immunophenotypic abnormalities causing or closely related to the inadequate production of hematopoietic cells that ultimately cause of cytopenias. The constellation of antigens expressed or miss expressed in this group of patients highlights the complexity of studying MDS by FC, and explains the great variability found in publications addressing the role of FC in the study of such an intrinsically heterogeneous disease. The “Consensus for the study of patients with MDS by Flow Cytometry” recently elaborated by the Grupo Rioplatense de Citometría de Flujo (GRCF), is our first step towards standardization of the process. The GRCF is committed to continue its quest towards achieving more consistent technical and analytical procedures, and thereby optimize actual strategies for evaluating this group of patients
Key words: Myelodisplastic syndromes, flow cytometry, standarization, consensus, GRCF.
Pages : 114-12
|
